Shuanghu Yuan

List of Publications by Year
in descending order

66 papers	1,587 citations	331538 21 h-index	330025 37 g-index
73 all docs	73 docs citations	73 times ranked	2003 citing authors

#	Article	IF	Citations
1	The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1679-1690.	1.2	4
2	CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy. European Radiology, 2022, 32, 1538-1547.	2.3	19
3	Upfront brain radiotherapy improves intracranial progression-free survival but not overall survival in lung adenocarcinoma patients with brain metastases: a retrospective, single-institutional analysis from China. Journal of Cancer, 2022, 13, 602-609.	1.2	2
4	Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation. Cancer Research and Treatment, 2022, 54, 1209-1218.	1.3	5
5	Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Journal of Translational Medicine, 2022, 20, 63.	1.8	3
6	[18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2761-2773.	3.3	26
7	Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors. Frontiers in Oncology, 2022, 12, 837952.	1.3	17
8	Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1165-1176.	0.4	8
9	[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1671-1681.	3.3	28
10	Exploration of spatial distribution of brain metastasis from small cell lung cancer and identification of metastatic risk level of brain regions: a multicenter, retrospective study. Cancer Imaging, 2021, 21, 41.	1.2	7
11	Rare NF1 Gene Mutation in Chinese Patient with Neurofibromatosis Type 1 and Anaplastic Astrocytoma. World Neurosurgery, 2020, 134, 434-437.	0.7	2
12	Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters, 2020, 472, 108-118.	3.2	8
13	18F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1324-1332.	1.3	18
14	Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study. Radiation Oncology, 2020, 15, 70.	1.2	13
15	Combination of DCE-MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma. BioMed Research International, 2020, 2020, 1-9.	0.9	2
16	Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [18F]Alfatide versus [18F]FDG. Molecular Imaging and Biology, 2019, 21, 175-182.	1.3	9
17	Association of Twice-Daily Radiotherapy With Subsequent Brain Metastases in Adults With Small Cell Lung Cancer. JAMA Network Open, 2019, 2, e190103.	2.8	18
18	Dosimetric evaluation of four whole brain radiation therapy approaches with hippocampus and inner ear avoidance and simultaneous integrated boost for limited brain metastases. Radiation Oncology, 2019, 14, 46.	1.2	18

#	ARTICLE	IF	CITATIONS
19	Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis. BioMed Research International, 2019, 2019, 1-15.	0.9	10
20	Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study. Melanoma Research, 2019, 29, 77-84.	0.6	41
21	Use CT Imaging to Predict the Short-Term Outcome of Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma. Dose-Response, 2019, 17, 155932581989717.	0.7	1
22	Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 940-947.	3.3	23
23	To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer. Molecular Imaging and Biology, 2018, 20, 1061-1067.	1.3	10
24	Prophylactic Cranial Irradiation in Non–Small-Cell Lung Cancer: Hope or Hype?. Journal of Clinical Oncology, 2018, 36, 3431-3432.	0.8	3
25	Integrated texture parameter of 18F-FDG PET may be a stratification factor for the survival of nonoperative patients with locally advanced non-small-cell lung cancer. Nuclear Medicine Communications, 2018, 39, 732-740.	0.5	6
26	Comparison of predictive powers of functional and anatomic dosimetric parameters for radiation-induced lung toxicity in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2018, 129, 242-248.	0.3	12
27	Surgery of primary tumor improves the survival of newly diagnosed metastatic melanoma: a population-based, propensity-matched study. Cancer Management and Research, 2018, Volume 11, 339-346.	0.9	4
28	18F–alfatide positron emission tomography may predict anti–angiogenic responses. Oncology Reports, 2018, 40, 2896-2905.	1.2	6
29	Magnetic resonance imaging evaluation of treatment efficacy and prognosis for brain metastases in lung cancer patients after radiotherapy: A preliminary study. Thoracic Cancer, 2018, 9, 865-873.	0.8	8
30	Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer. Scientific Reports, 2017, 7, 42743.	1.6	13
31	A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer. Scientific Reports, 2017, 7, 2877.	1.6	21
32	To Find a Better Dosimetric Parameter in the Predicting of Radiation-Induced Lung Toxicity Individually: Ventilation, Perfusion or CT based. Scientific Reports, 2017, 7, 44646.	1.6	2
33	Is it time to convert the frequency of radiotherapy in small-cell lung cancer?. Lancet Oncology, The, 2017, 18, e553.	5.1	2
34	A novel molecular agent for glioma angiogenesis imaging. Nuclear Medicine Communications, 2017, 38, 919-926.	0.5	2
35	Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis. OncoTargets and Therapy, 2017, Volume 10, 2087-2095.	1.0	25
36	Late-Course Adaptive Adjustment Based on Metabolic Tumor Volume Changes during Radiotherapy May Reduce Radiation Toxicity in Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2017, 12, e0170901.	1.1	11

#	Article	IF	Citations
37	An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk. Oncotarget, 2017, 8, 28888-28896.	0.8	8
38	Fluorine-18 labeled amino acids for tumor PET/CT imaging. Oncotarget, 2017, 8, 60581-60588.	0.8	27
39	Combined neutrophil-platelet score and hemoglobin level predict survival in esophageal squamous cell carcinoma patients treated with chemoradiotherapy. Oncotarget, 2017, 8, 87971-87979.	0.8	10
40	MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4. Oncotarget, 2016, 7, 74059-74073.	0.8	51
41	A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. PLoS ONE, 2016, 11, e0157606.	1.1	19
42	18F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2336-2342.	3.3	32
43	Stereotactic Comparison Study of 18F-Alfatide and 18F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model. Scientific Reports, 2016, 6, 28757.	1.6	4
44	Can an ^{18}F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?. Journal of Nuclear Medicine, 2016, 57, 524-529.	2.8	40
45	A pilot study imaging integrin $\alpha v \beta 3$ with RGD PET/CT in suspected lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 2029-2037.	3.3	52
46	Noninvasive Evaluation of Metabolic Tumor Volume in Lewis Lung Carcinoma Tumor-Bearing C57BL/6 Mice with Micro-PET and the Radiotracers 18F-Alfatide and 18F-FDG: A Comparative Analysis. PLoS ONE, 2015, 10, e0136195.	1.1	3
47	Circulating Tumor Cells Correlate with Recurrence in Stage III Small-cell Lung Cancer after Systemic Chemoradiotherapy and Prophylactic Cranial Irradiation. Japanese Journal of Clinical Oncology, 2014, 44, 948-955.	0.6	11
48	Radioactive Self-Expanding Stents Give Superior Palliation in Patients With Unresectable Cancer of the Esophagus but Should Be Used With Caution ifÂThey Have Had Prior Radiotherapy. Annals of Thoracic Surgery, 2014, 98, 521-526.	0.7	17
49	Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. Radiation Oncology, 2014, 9, 37.	1.2	22
50	Metabolic tumor volume on PET reduced more than gross tumor volume on CT during radiotherapy in patients with non-small cell lung cancer treated with 3DCRT or SBRT. Journal of Radiation Oncology, 2013, 2, 191-202.	0.7	30
51	Poor Baseline Pulmonary Function May Not Increase the Risk of Radiation-Induced Lung Toxicity. International Journal of Radiation Oncology Biology Physics, 2013, 85, 798-804.	0.4	50
52	Genetic Variations in TGF$\beta 1$, tPA, and ACE and Radiation-Induced Thoracic Toxicities in Patients with Nonâ€"Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 208-213.	0.5	19
53	Changes in Global Function and Regional Ventilation and Perfusion on SPECT During the Course of Radiotherapy in Patients With Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e631-e638.	0.4	46
54	Combining Physical and Biologic Parameters to Predict Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer Treated With Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, e217-e222.	0.4	88

#	Article	IF	Citations
55	Erlotinib Resistance is Altered after Gemcitabine Chemotherapy for Recurrent Non-Small-Cell Lung Cancer. Clinical Drug Investigation, 2011, 31, 279-283.	1.1	0
56	Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cancer: Potential Indication for Radiotherapy Planning. Journal of Thoracic Oncology, 2011, 6, 71-78.	0.5	37
57	Acute Inhibition of Rho-Kinase Attenuates Pulmonary Hypertension in Patients with Congenital Heart Disease. Pediatric Cardiology, 2009, 30, 363-366.	0.6	56
58	Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. European Journal of Radiology, 2009, 70, 320-324.	1.2	31
59	Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer. Lung Cancer, 2009, 63, 383-386.	0.9	26
60	Erratum to â€œValue of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancerâ€•[Lung Cancer 61 (2008) 35â€"43]. Lung Cancer, 2009, 63, 305.	0.9	0
61	Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer, 2008, 61, 35-43.	0.9	70
62	Diagnostic and Prognostic Value of 18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the Esophagus. Journal of Nuclear Medicine, 2007, 48, 1251-1258.	2.8	74
63	A Randomized Study of Involved-Field Irradiation Versus Elective Nodal Irradiation in Combination With Concurrent Chemotherapy for Inoperable Stage III Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 239-244.	0.6	229
64	Determining optimal clinical target volume margins on the basis of microscopic extracapsular extension of metastatic nodes in patients with nonâ€"small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 727-734.	0.4	43
65	Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Journal of Nuclear Medicine, 2006, 47, 1255-9.	2.8	83
66	Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	2